Global Personal Robots Market to Record 37.8% CAGR During 2016 – 2022     |    Global E-Cigarette Market to Witness 16.6% CAGR During 2016 – 2022     |    Global Needle-Free Diabetes Management Market to Witness 17.8% CAGR During 2017 – 2025

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

P&S Market Research - A market research firm

Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis

P&S Market Research-Idiopathic Pulmonary Fibrosis Therapeutics Market report

Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: February 2017
Report Code: LS10753
Available Format: pdf
Pages: 183

Pipeline Overview

Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs becomes stiff and dense over time. The scar tissue formation is known as fibrosis. As the fibrosis progresses and tissue become darker, lungs can't properly move oxygen into the bloodstream, which result in oxygen deficiency in brain and other organs.

IPF usually affects older adults and middle-aged people and it has no cure till now. The major cause of death in IPF’s patients is respiratory failure. Pulmonary hypertension, heart failure, pulmonary embolism, pneumonia and lung cancer are the other causes of the death for IPF patient. With the progress in research for IPF, it is now more quickly diagnosed and many drugs are also being discovered for its treatment. This will improve the quality of life of patients and will also increase their lifespan.

Bronchoscopy and surgical lung biopsy are used as testing procedures. In Bronchoscopy, lymphocytosis in bronchoalveolar lavage fluid is absent which is observed for the diagnosis. The best sample for characteristic usual interstitial pneumonia from other idiopathic interstitial pneumonias is surgical lung biopsy. The treatment for IPF as optimal medical cure has yet to be identified. This creates ample growth opportunities for pharmaceutical companies, as there is very low competition due to lack of approved drugs.

Current treatment approaches for IPF include the management and assessment of comorbid conditions per present practice guidelines, including obstructive sleep apnea, chronic obstructive pulmonary disease, coronary artery disease and gastroesophageal reflux disease. Other strategies for IPF include surgery and pharmacotherapy. This further fuels the demand for the development of therapeutics for IPF treatment.

Pipeline Analysis

The IPF pipeline is very strong with a total of 97 drug candidates. Pharma giant such as Asahi Kasei Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the development of the IPF therapeutics. The IPF pipeline comprised of 97 product candidates, of which one is in Phase III stage, 15 are in Phase II stage, 12 are in Phase I stage, 39 are in Pre-clinical stage, and seven are in discovery stage.

SM04646 is under Phase I stage of development by Samumed, LLC for the treatment of IPF. The drug candidate is a small molecule that acts as Wnt pathway modulator. Samumed is using the technology for development of small molecule that modulate Wnt pathway. The technology is not a stem cell therapy, instead focusing on the modulation of the Wnt pathway that recovers and restores the health of diseased tissues and presents significant opportunities in regenerative therapeutics.

Competitive Landscape

Several companies are involved in IPF with their products in different phases. The only Phase III IPF drug candidate is being developed by Asahi Kasei Pharma Corporation. The IPF pipeline drug candidates of Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG and FibroGen, Inc. are in Phase II stage of development. Bristol-Myers Squibb Company is also having its IPF pipeline drug candidates in different clinical stages, including two drugs in Phase II and one drug in Phase I. Some of the key players developing drug candidates for the treatment of IPF  are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Chapter 1. Research Scope and Methodology

1.1 Research Scope

1.2 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Pipeline Outlook

3.1 Overview

3.2 Idiopathic Pulmonary Fibrosis Pipeline Analysis

3.2.1 Pipeline analysis by target

3.2.2 Pipeline analysis by route of administration

3.2.3 Pipeline analysis by company

3.2.4 Discontinued drug candidates

3.2.5 Inactive drug candidates

Chapter 4. Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis by Phase (2016)

4.1 Phase III

4.1.1 Thrombomodulin Alfa

4.1.1.1 Clinical trials

4.2 Phase II

4.2.1 Lebrikizumab

4.2.1.1 Clinical trials

4.2.1.2 Strategic development

4.2.2 Tipelukast

4.2.2.1 Clinical trials

4.2.2.2 Strategic development

4.2.3 KD025

4.2.3.1 Clinical trials

4.2.4 MK-7624

4.2.4.1 Clinical trials

4.2.4.2 Strategic development

4.2.5 GLPG1690

4.2.5.1 Clinical trials

4.2.5.1.1 Clinical results

4.2.5.2 Strategic development

4.2.6 LT-1001

4.2.6.1 Strategic development

4.2.6.2 Technology

4.2.7 BG00011

4.2.7.1 Clinical trials

4.2.7.2 Strategic development

4.2.8 BMS-986020

4.2.8.1 Clinical trials

4.2.9 LT-1002

4.2.9.1 Technology

4.2.10 Pamrevlumab

4.2.10.1 Clinical trials

4.2.10.1.1 Clinical results

4.2.10.2 Strategic development

4.2.10.3 Technology

4.2.11 PRM 151

4.2.11.1 Clinical trials

4.2.11.2 Strategic development

4.2.12 GBT 440

4.2.12.1 Clinical trials

4.2.12.2 Technology

4.2.13 PBI4050

4.2.13.1 Clinical trials

4.2.13.2 Strategic development

4.2.13.2.1 Designation

4.2.14 SAR156597

4.2.14.1 Clinical trials

4.2.15 BMS 986036

4.2.15.1 Strategic development

4.2.15.2 Technology

4.3 Phase I

4.3.1 PEG-FGF21

4.3.2 IW001

4.3.2.1 Clinical trials

4.3.2.2 Results

4.3.3 MMI-0100

4.3.3.1 Clinical trials

4.3.3.2 Strategic development

4.3.3.3 Technology

4.3.4 ZL-2102

4.3.4.1 Clinical trials

4.3.4.2 Strategic development

4.3.5 AEOL 10150

4.3.5.1 Strategic development

4.3.6 CC-90001

4.3.6.1 Clinical trials

4.3.7 Vismodegib

4.3.7.1 Clinical trials

4.3.7.2 Strategic development

4.3.8 SD-560

4.3.8.1 Strategic development

4.3.9 GSK3008348

4.3.9.1 Clinical trials

4.3.10 Omipalisib

4.3.10.1 Clinical trials

4.3.11 (Pentoxifylline + Acetylcysteine)

4.3.12 SM04646

4.3.12.1 Clinical trials

4.3.12.2 Technology

4.4 Pre-clinical

4.4.1 MOR107

4.4.1.1 Strategic development

4.4.1.2 Technology

4.4.2 IBIO-CFB03

4.4.2.1 Strategic development

4.4.3 HEC585

4.4.4 HC-016

4.4.5 IVA 337

4.4.5.1 Strategic development

4.4.6 ISTH 1106

4.4.6.1 Strategic development

4.4.7 KBP-7018

4.4.8 SPL-334

4.4.8.1 Strategic development

4.4.8.2 Technology

4.4.9 SPL-891

4.4.9.1 Strategic development

4.4.9.2 Technology

4.4.10 RT234

4.4.10.1 Technology

4.4.11 Sting-Antagonists

4.4.11.1 Strategic development

4.4.12 LTI-03

4.4.12.1 Strategic development

4.4.13 αvβ1 Integrin Program

4.4.13.1 Strategic development

4.4.14 Small molecule to target Integrin 2

4.4.14.1 Strategic development

4.4.15 C188-9

4.4.16 PUR1500

4.4.16.1 Strategic development

4.4.16.2 Technology

4.4.17 MSM-735

4.4.17.1 Technology

4.4.18 PBI-4425

4.4.19 AD-114

4.4.19.1 Strategic development

4.4.19.2 Technology

4.4.20 Neumomir

4.4.20.1 Pre-clinical studies

4.4.21 SAMiRNA prodrug

4.4.21.1 Pre-clinical studies

4.4.21.2 Strategic development

4.4.21.3 Technology

4.4.22 Cabiralizumab

4.4.22.1 Strategic development

4.4.23 GR-MD-02

4.4.23.1 Pre-clinical studies

4.4.23.2 Strategic development

4.4.24 GKT831

4.4.24.1 Pre-clinical studies

4.4.25 OLX-201

4.4.25.1 Technology

4.4.26 HL-156FIB

4.4.26.1 Pre-clinical studies

4.4.27 PBF-1129

4.4.27.1 Pre-clinical studies

4.4.28 P007

4.4.28.1 Strategic development

4.4.28.2 Technology

4.4.29 RBM-005

4.4.29.1 Technology

4.4.30 RBM-003

4.4.30.1 Technology

4.4.31 RBM-006

4.4.31.1 Technology

4.4.32 RBM-007

4.4.32.1 Technology

4.4.33 RP-6503

4.4.33.1 Strategic development

4.4.34 CM-101

4.4.34.1 Technology

4.4.35 GBT-1118

4.4.36 KTN-0158

4.4.36.1 Strategic development

4.4.37 ST2001

4.4.38 BOT191

4.4.38.1 Technology

4.5 Discovery

4.5.1 LOXL2 Inhibitor

4.5.1.1 Strategic development

4.5.2 Small molecule to target EMT

4.5.2.1 Strategic development

4.5.3 TGF-β related target

4.5.3.1 Strategic development

4.5.4 Integrin target 3

4.5.4.1 Strategic development

4.5.5 Drug for Idiopathic Pulmonary Fibrosis

4.5.5.1 Technology

4.5.6 P013

4.5.6.1 Strategic development

4.5.6.2 Technology

4.5.7 Small Molecule for IPF

4.5.7.1 Strategic development

Chapter 5. SWOT Analysis of Idiopathic Pulmonary Fibrosis Pipeline

Chapter 6. Company Profiles and Strategic Developments

6.1 Key Company Profiles

6.1.1 Bristol-Myers Squibb Company

6.1.1.1 Business overview

6.1.1.2 Product and service offerings

6.1.2 F. Hoffmann-La Roche Ltd.

6.1.2.1 Business overview

6.1.2.2 Product and service offerings

6.1.3 Merck & Co., Inc.

6.1.3.1 Business overview

6.1.3.2 Product and service offerings

6.1.4 Global Blood Therapeutics, Inc.

6.1.4.1 Business overview

6.1.4.2 Product and service offerings

6.1.5 Asahi Kasei Corporation

6.1.5.1 Business overview

6.1.5.2 Product and service offerings

6.1.6 Beijing Tide Pharmaceutical Co., Limited

6.1.6.1 Business overview

6.1.6.2 Product and service offerings

6.1.7 FibroGen, Inc.

6.1.7.1 Business overview

6.1.7.2 Product and service offerings

6.1.8 Chong Kun Dang Pharmaceutical Corp.

6.1.8.1 Business overview

6.1.8.2 Product and service offerings

6.1.9 Galapagos NV

6.1.9.1 Business overview

6.1.9.2 Product and service offerings

6.1.10 Kadmon Holdings, Inc.

6.1.10.1 Business overview

6.1.10.2 Product and service offerings

6.1.11 MediciNova, Inc.

6.1.11.1 Business overview

6.1.11.2 Product and service offerings

6.1.12 Promedior, Inc.

6.1.12.1 Business overview

6.1.12.2 Product and service offerings

Chapter 7. Appendix

7.1 List of Abbreviations

 

LIST OF TABLES 

TABLE 1: SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2: PIPELINE ANALYSIS OF IPF BY COMPANY (2016)

TABLE 3: DISCONTINUED IPF DRUG CANDIDATES (2016)

TABLE 4: INACTIVE IPF DRUG CANDIDATES (2016)

TABLE 5: CLINICAL TRIALS OF THROMBOMODULIN ALFA

TABLE 6: DESCRIPTION OF THROMBOMODULIN ALFA

TABLE 7: CLINICAL TRIALS OF LEBRIKIZUMAB

TABLE 8: DESCRIPTION OF LEBRIKIZUMAB

TABLE 9: CLINICAL TRIALS OF TIPELUKAST

TABLE 10: DESCRIPTION OF TIPELUKAST

TABLE 11: CLINICAL TRIALS OF KD025

TABLE 12: DESCRIPTION OF KD025

TABLE 13: CLINICAL TRIALS OF MK-7624

TABLE 14: DESCRIPTION OF MK-7624

TABLE 15: CLINICAL TRIALS OF GLPG1690

TABLE 16: DESCRIPTION OF GLPG1690

TABLE 17: DESCRIPTION OF LT-1001

TABLE 18: CLINICAL TRIALS OF BG00011

TABLE 19: DESCRIPTION OF BG00011

TABLE 20: CLINICAL TRIALS OF BMS-986020

TABLE 21: DESCRIPTION OF BMS-986020

TABLE 22: DESCRIPTION OF LT-1002

TABLE 23: CLINICAL TRIALS OF PAMREVLUMAB

TABLE 24: DESCRIPTION OF PAMREVLUMAB

TABLE 25: CLINICAL TRIALS OF PRM 151

TABLE 26: DESCRIPTION OF PRM 151

TABLE 27: CLINICAL TRIALS OF GBT440

TABLE 28: DESCRIPTION OF GBT440

TABLE 29: CLINICAL TRIALS OF PBI-4050

TABLE 30: DESCRIPTION OF PBI-4050

TABLE 31: CLINICAL TRIALS OF SAR156597

TABLE 32: DESCRIPTION OF SAR156597

TABLE 33: DESCRIPTION OF BMS 986036

TABLE 34: DESCRIPTION OF PEG-FGF21

TABLE 35: CLINICAL TRIALS OF IW001

TABLE 36: DESCRIPTION OF IW001

TABLE 37: CLINICAL TRIALS OF MMI-0100

TABLE 38: DESCRIPTION OF MMI-0100

TABLE 39: CLINICAL TRIALS OF ZL-2102

TABLE 40: DESCRIPTION OF ZL-2102

TABLE 41: DESCRIPTION OF AEOL 10150

TABLE 42: CLINICAL TRIALS OF CC-90001

TABLE 43: DESCRIPTION OF CC-90001

TABLE 44: CLINICAL TRIALS OF VISMODEGIB

TABLE 45: DESCRIPTION OF VISMODEGIB

TABLE 46: DESCRIPTION OF SD-560

TABLE 47: CLINICAL TRIALS OF GSK3008348

TABLE 48: DESCRIPTION OF GSK3008348

TABLE 49: CLINICAL TRIALS OF OMIPALISIB

TABLE 50: DESCRIPTION OF OMIPALISIB

TABLE 51: DESCRIPTION OF (PENTOXIFYLLINE + ACETYLCYSTEINE)

TABLE 52: CLINICAL TRIALS OF SM04646

TABLE 53: DESCRIPTION OF SM04646

TABLE 54: DESCRIPTION OF MOR107

TABLE 55: DESCRIPTION OF IBIO-CFB03

TABLE 56: DESCRIPTION OF HEC585

TABLE 57: DESCRIPTION OF HC-016

TABLE 58: DESCRIPTION OF IVA 337

TABLE 59: DESCRIPTION OF ISTH 1106

TABLE 60: DESCRIPTION OF KBP-7018

TABLE 61: DESCRIPTION OF SPL-334

TABLE 62: DESCRIPTION OF SPL-891

TABLE 63: DESCRIPTION OF RT234

TABLE 64: DESCRIPTION OF STING-ANTAGONISTS

TABLE 65: DESCRIPTION OF LTI-03

TABLE 66: DESCRIPTION OF ΑVΒ1 INTEGRIN PROGRAM

TABLE 67: DESCRIPTION OF SMALL MOLECULE TO TARGET INTEGRIN 2

TABLE 68: DESCRIPTION OF C188-9

TABLE 69: DESCRIPTION OF PUR1500

TABLE 70: DESCRIPTION OF MSM-735

TABLE 71: DESCRIPTION OF PBI-4425

TABLE 72: DESCRIPTION OF AD-114

TABLE 73: DESCRIPTION OF NEUMOMIR

TABLE 74: DESCRIPTION OF SAMIRNA PRODRUG

TABLE 75: DESCRIPTION OF CABIRALIZUMAB

TABLE 76: DESCRIPTION OF GR-MD-02

TABLE 77: DESCRIPTION OF GKT831

TABLE 78: DESCRIPTION OF OLX-201

TABLE 79: DESCRIPTION OF HL156FIB

TABLE 80: DESCRIPTION OF PBF-1129

TABLE 81: DESCRIPTION OF P007

TABLE 82: DESCRIPTION OF RBM-005

TABLE 83: DESCRIPTION OF RBM-003

TABLE 84: DESCRIPTION OF RBM-006

TABLE 85: DESCRIPTION OF RBM-007

TABLE 86: DESCRIPTION OF RP-6503

TABLE 87: DESCRIPTION OF CM-101

TABLE 88: DESCRIPTION OF GBT-1118

TABLE 89: DESCRIPTION OF KTN-0158

TABLE 90: DESCRIPTION OF ST2001

TABLE 91: DESCRIPTION OF BOT191

TABLE 92: DESCRIPTION OF LOXL2 INHIBITOR

TABLE 93: DESCRIPTION OF SMALL MOLECULE TO TARGET EMT

TABLE 94: DESCRIPTION OF TGF-Β RELATED TARGET

TABLE 95: DESCRIPTION OF INTEGRIN TARGET 3

TABLE 96: DESCRIPTION OF DRUG FOR IDIOPATHIC PULMONARY FIBROSIS

TABLE 97: DESCRIPTION OF P013

TABLE 98: DESCRIPTION OF SMALL MOLECULE FOR IPF

TABLE 99: SWOT ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS

TABLE 100: BRISTOL-MYERS SQUIBB COMPANY– KEY FACTS

TABLE 101: F. HOFFMANN-LA ROCHE LTD. – KEY FACTS

TABLE 102: MERCK & CO., INC. – KEY FACTS

TABLE 103: GLOBAL BLOOD THERAPEUTICS – KEY FACTS

TABLE 104: ASAHI KASEI CORPORATION – KEY FACTS

TABLE 105: BEIJING TIDE PHARMACEUTICAL CO., LIMITED – KEY FACTS

TABLE 106: FIBROGEN, INC. – KEY FACTS

TABLE 107: CHONG KUN DANG PHARMACEUTICAL CORP. – KEY FACTS

TABLE 108: GALAPAGOS NV – KEY FACTS

TABLE 109: KADMON HOLDINGS, INC. – KEY FACTS

TABLE 110: MEDICINOVA, INC. – KEY FACTS

TABLE 111: PROMEDIOR, INC. – KEY FACTS

 

LIST OF FIGURES 

FIG 1: NUMBER OF IPF PRODUCTS UNDER DEVELOPMENT (2016)

FIG 2: GLOBAL IPF PIPELINE SPLIT, BY TARGET (2016)

FIG 3: GLOBAL IPF PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2016)

The research offers pipeline analysis of idiopathic pulmonary fibrosis (IPF) to estimate and analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action and drug origin with relevance to IPF.

IPF PIPELINE ANALYSIS

  • By target
  • By route of administration
  • By company
  • By phase

Please fill the form to get the sample pages.

  

Select License Type

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

$6500
Group License

Group License authorizes access of the publication upto 5 users.

$7500
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

$8500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

$11500
down-arrow

Pre-Purchase Enquiry